By
Drug Target Review2026-01-15T10:10:53
Researchers have shown that changing the molecular structure of NK1 receptor antagonists may restore antidepressant effects after decades of failed trials.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-06-19T08:26:00Z
2026-06-17T12:40:00Z
2026-05-22T07:38:00
Contributor Dr Helen Bright, By Drug Target Review
2023-01-05T14:41:33
Sponsored by Cell Signaling Technology
2023-09-27T10:36:50
Sponsored by NanoTemper Technologies
2024-01-09T09:30:19
Sponsored by Sartorius
Site powered by Webvision Cloud